NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics (NASDAQ:NLNK) in a research note issued to investors on Monday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also issued reports on NLNK. Stifel Nicolaus increased their price objective on NewLink Genetics from $14.00 to $29.00 and gave the stock a buy rating in a research note on Monday, September 11th. ValuEngine lowered NewLink Genetics from a hold rating to a sell rating in a research note on Wednesday, September 13th. Bank of America assumed coverage on NewLink Genetics in a research note on Friday, October 13th. They set a buy rating and a $22.00 price objective for the company. BidaskClub upgraded NewLink Genetics from a sell rating to a hold rating in a research note on Friday, January 5th. Finally, Jefferies Group dropped their price objective on NewLink Genetics from $26.00 to $25.00 and set a buy rating for the company in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. NewLink Genetics presently has a consensus rating of Buy and an average price target of $23.29.

Shares of NewLink Genetics (NASDAQ NLNK) traded up $0.14 during midday trading on Monday, hitting $8.58. The company had a trading volume of 739,632 shares, compared to its average volume of 1,120,270. The firm has a market capitalization of $310.78, a price-to-earnings ratio of -3.52 and a beta of 1.10. NewLink Genetics has a twelve month low of $5.90 and a twelve month high of $25.17.

A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its stake in NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares in the last quarter. Advisor Group Inc. raised its stake in NewLink Genetics by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 600 shares in the last quarter. First Trust Advisors LP raised its stake in NewLink Genetics by 11.1% during the second quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 2,859 shares in the last quarter. Wells Fargo & Company MN raised its stake in NewLink Genetics by 1.8% during the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock worth $1,219,000 after acquiring an additional 2,865 shares in the last quarter. Finally, State Street Corp increased its stake in shares of NewLink Genetics by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after buying an additional 4,630 shares in the last quarter. Hedge funds and other institutional investors own 52.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald” was originally reported by Zolmax and is the sole property of of Zolmax. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://zolmax.com/investing/newlink-genetics-nlnk-given-a-26-00-price-target-at-cantor-fitzgerald/1884320.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Westlake Chemical  Earns Daily Coverage Optimism Score of 0.07
Westlake Chemical Earns Daily Coverage Optimism Score of 0.07
Somewhat Positive News Coverage Somewhat Unlikely to Impact Advanced Semiconductor Engnrng  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact Advanced Semiconductor Engnrng Stock Price
SVB Financial Group  Given News Impact Score of 0.43
SVB Financial Group Given News Impact Score of 0.43
CVR Partners LP  Given Consensus Recommendation of “Hold” by Brokerages
CVR Partners LP Given Consensus Recommendation of “Hold” by Brokerages
Prologis  Earns Daily Media Sentiment Rating of 0.06
Prologis Earns Daily Media Sentiment Rating of 0.06
KKR & Co. L.P.  Receiving Somewhat Favorable News Coverage, Report Shows
KKR & Co. L.P. Receiving Somewhat Favorable News Coverage, Report Shows


Leave a Reply

 
© 2006-2018 Zolmax.